Use of programmed cell death protein 1 (PD-1) inhibitor therapy in HIV-infected patients with advanced cancer: a single-center study from China

Abstract Background Anti-PD-1 antibodies have been approved for treating several cancer. However, data regarding the safety and efficacy of these agents in HIV-infected patients with cancer is lacking, because these patients are frequently omitted from clinical trials. Objectives The primary aim of...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Luling Wu, Jie Su, Junyang Yang, Ling Gu, Renfang Zhang, Li Liu, Hongzhou Lu, Jun Chen
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	BMC 2023-05-01
Sarja:	Infectious Agents and Cancer
Aiheet:	HIV Cancer PD-1 ICIs Safety and outcomes
Linkit:	https://doi.org/10.1186/s13027-023-00512-z
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!